

Teva Reports Q4 and Full Year 2020 Business Results



|| In 2020, Teva continued to provide essential medicines to millions of patients around the world every day, and despite the COVID-19 pandemic challenges, we saw minimal impact on our supply chain, R&D programs and product launches. Following a strong fourth quarter performance, we have met all components of our 2020 financial guidance.

Our key growth drivers delivered promising results and milestones, including the continued growth of AUSTEDO® and our leading biosimilar TRUXIMA®, as AJOVY® sales continued to improve following the launch of the auto-injector. Our generic performance was boosted by the successful launch of the generic versions of HIV-1 treatments Truvada® and Atripla® tablets in the U.S. We have also taken steps to strengthen our biopharmaceutical pipeline, with a biosimilar commercialization agreement, and are advancing other pipeline assets, including the recently announced positive results from the phase 3 trial of risperidone extended-release injectable for patients with schizophrenia.

Looking ahead, we will continue to optimize our manufacturing network, portfolio and pipeline, improve our profitability and generate cash, as we remain on track to repay our debt and achieve our long-term financial targets. **||**

Kåre Schultz

President & Chief Executive Officer

2020 Financial Results - Meeting all guidance targets



Revenue



EPS*



Free Cash Flow

Q4 results:

\$4.5 billion

\$0.68

\$471 million

**2020 full
year results**

\$16.7 billion

\$2.57

\$2.1 billion


**2020 revised
guidance:**

\$16.5- \$16.8 billion

\$2.40 - \$2.55

*Non-GAAP EPS

\$1.8 - \$2.2 billion



Teva's Response to COVID-19

Business Continuity

~**200 million** patients continue to have access to our essential medicines

Minimal impact to our **R&D programs** and **product launches**



Sourcing & Production

Our facilities remained open to meet demand for our essential medicines



Adequate inventory of raw materials and finished products across our global network

Safe supply and transport of our medicines and APIs remains largely uninterrupted

Our Employees

The **health and well-being** of our employees is our priority



No job losses related to COVID-19



Our Communities

Supporting local government and healthcare efforts to curb the pandemic

Millions of tablets of **investigational treatments** provided to governments and hospitals

Millions of **COVID-19 vaccines** distributed by Teva in Israel

Key Products - Leveraging our growth engines in 2020:

AJOVY®

Auto-injector launched in the U.S.; launch throughout EU; launched in 5 additional international markets

AUSTEDO®

Continued strong growth in the U.S.; approved in China for the treatment of Chorea associated with Huntington disease and for Tardive Dyskinesia

Biosimilars

TRUXIMA® 24% market share in the U.S.; new biosimilar commercialization agreement strengthens our pipeline


DigiHaler®

Launched three digital inhalers in the U.S.: ProAir®, ArmonAir®, AirDuo®; cloud platform collaboration with Amazon Web Services

Continuing to bring down our debt

Net Debt Development

\$ billions



Looking ahead to 2021

Our 2021 Guidance



Revenue

\$16.4 - \$16.8 billion



EPS*

\$2.50 - \$2.70

*Non-GAAP EPS



Free Cash Flow

\$2.0 - \$2.3 billion

Announced 2030 Long-Term Environmental Targets



CLIMATE ACTION & RESILIENCE

- Reduce **Scope 1 and 2 greenhouse gas (GHG) emissions by 33%**
- Support efforts to limit global temperature increase to well below 2°C
- Aligned with the 2015 Paris Climate Agreement



RESPONSIBLE USE OF NATURAL RESOURCES

- Increase **energy efficiency by 10%**
- Increase energy from **renewable sources to 50%**
- Reduce total **water withdrawal by 10%**



EMISSIONS, EFFLUENTS AND WASTE

- Increase proportion of **recycled and responsibly-sourced materials by 10%**
- Continue to **minimize waste**
- **Minimize antimicrobial discharges** from supply chain

Improved ESG Performance Across Multiple Benchmarks

	2020 Score	2020 Sector Ranking		Previous Score
 SUSTAINALYTICS	65	Top 10%	⬆️	63
 SAM Now a Part of 	36	Top 30%	⬆️	33
 CDP	A-	Top 38%	⬆️	Top 38%
 ISS ESG	C	Top 40%	⬆️	D+
 FTSE4Good	3.4	Top 29%	✓	3.9
 MSCI	B	Bottom 22%	➡️	B
 ecovadis	56	Top 23%	➡️	56
 access to medicine FOUNDATION	22	Top 22%	⬆️	9

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Infographic contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management's current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to:

- our ability to successfully compete in the marketplace, including: that we are substantially dependent on our generic products; consolidation of our customer base and commercial alliances among our customers; delays in launches of new generic products; the increase in the number of competitors targeting generic opportunities and seeking U.S. market exclusivity for generic versions of significant products; our ability to develop and commercialize biopharmaceutical products; competition for our specialty products, including AUSTEDO®, AJOVY® and COPAXONE®; our ability to achieve expected results from investments in our product pipeline; our ability to develop and commercialize additional pharmaceutical products; and the effectiveness of our patents and other measures to protect our intellectual property rights;
- our substantial indebtedness, which may limit our ability to incur additional indebtedness, engage in additional transactions or make new investments, may result in a further downgrade of our credit ratings; and our inability to raise debt or borrow funds in amounts or on terms that are favorable to us;
- our business and operations in general, including: uncertainty regarding the magnitude, duration, and geographic reach of the COVID-19 pandemic and its impact on our business, financial condition, operations, cash flows, and liquidity and on the economy in general; our ability to successfully execute and maintain the activities and efforts related to the measures we have taken or may take in response to the COVID-19 pandemic and associated costs therewith; effectiveness of our optimization efforts; our ability to attract, hire and retain highly skilled personnel; manufacturing or quality control problems; interruptions in our supply chain; disruptions of information technology systems; breaches of our data

security; variations in intellectual property laws; challenges associated with conducting business globally, including political or economic instability, major hostilities or terrorism; costs and delays resulting from the extensive pharmaceutical regulation to which we are subject or delays in governmental processing time due to travel and work restrictions caused by the COVID-19 pandemic; the effects of reforms in healthcare regulation and reductions in pharmaceutical pricing, reimbursement and coverage; significant sales to a limited number of customers; our ability to successfully bid for suitable acquisition targets or licensing opportunities, or to consummate and integrate acquisitions; and our prospects and opportunities for growth if we sell assets;

- compliance, regulatory and litigation matters, including: failure to comply with complex legal and regulatory environments; increased legal and regulatory action in connection with public concern over the abuse of opioid medications and our ability to reach a final resolution of the remaining opioid-related litigation; scrutiny from competition and pricing authorities around the world, including our ability to successfully defend against the U.S. Department of Justice ("DOJ") criminal charges of Sherman Act violations; potential liability for patent infringement; product liability claims; failure to comply with complex Medicare and Medicaid reporting and payment obligations; compliance with anti-corruption sanctions and trade control laws; and environmental risks;
- other financial and economic risks, including: our exposure to currency fluctuations and restrictions as well as credit risks; potential impairments of our intangible assets; potential significant increases in tax liabilities; and the effect on our overall effective tax rate of the termination or expiration of governmental programs or tax benefits, or of a change in our business;

and other factors discussed in our Annual Report on Form 10-K for the year ended December 31, 2020, including the sections captioned "Risk Factors." Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.